Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04958122 · ClinicalTrials.gov registry record · Phase 3
Cefixime Clinical Trial
A Phase 3 study of Human Immunodeficiency Virus and Syphilis, sponsored by University of Southern California.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT04958122: Recruiting Phase 3 study of Human Immunodeficiency Virus and Syphilis, sponsored by University of Southern California.
NCT04958122 is a Phase 3 study of Human Immunodeficiency Virus and Syphilis that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 400 participants, above the 174-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (130% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04958122, a Phase 3 study of Human Immunodeficiency Virus and Syphilis, is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to evaluate the efficacy of cefixime compared to benzathine penicillin G in the treatment of syphilis.
Primary Outcome
Percentage of cefixime participants with a 4-fold decrease or greater in the serum RPR titer 3 or 6 months after treatment completion
Conditions Studied
Interventions
- DRUG Cefixime 400mg
- DRUG benzathine penicillin
Study Locations (1)
California
- University of Southern California - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2021-06-20 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 3 |
What NCT04958122 shows while recruiting
NCT04958122 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 174-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (130% higher).
The record links to 2 conditions, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 2 interventions - of which Cefixime 400mg is the first listed.
NCT04958122 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04958122 about?
NCT04958122 is a clinical study titled "Cefixime Clinical Trial". This study aims to evaluate the efficacy of cefixime compared to benzathine penicillin G in the treatment of syphilis.
What is the current status of trial NCT04958122?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2021-06-20. Estimated completion is 2027-06-30.
What conditions does trial NCT04958122 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus, Syphilis.
What interventions are being tested in trial NCT04958122?
The interventions under investigation include: Cefixime 400mg (DRUG), benzathine penicillin (DRUG).
Who is sponsoring clinical trial NCT04958122?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04958122 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04958122's enrollment target sits among peer trials
400 6th of 39 higher than 33 of 39 other Human Immunodeficiency Virus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Immunodeficiency Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
Baricitinib for Reduction of HIV - CNS
RECRUITING · Phase 2
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
RECRUITING
-
Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI